Bo xian Wu

Dr. Bo xian Wu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Heliyon
Verified
Journal Article
Open access
YXYihua Xu
Yihua Xu
LBLan Bai
Lan Bai
XYXinwei Yang
Xinwei Yang
JHJianli Huang
Jianli Huang
JWJie Wang
Jie Wang
JSJianyou Shi
Jianyou Shi
Inflammation is a complex physiological phenomenon, which is the body's defensive response, but abnormal inflammation can have adverse effects, and many diseases are related to the inflammatory response. AMPK, as a key sensor of cellular energy status, plays a crucial role in regulating cellular energy homeostasis and glycolipid metabolism. In recent years, the anti-inflammation effect of AMPK and related signalling cascade has begun to enter everyone's field of vision – not least the impact on metabolic diseases. A great number of studies have shown that anti-inflammatory drugs work through AMPK and related pathways.

12 June 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
LDLidan Deng
Lidan Deng
LWLi Wan
Li Wan
TLTingting Liao
Tingting Liao
LWLin Wang
Lin Wang
JWJie Wang
Jie Wang
JSJianyou Shi
Jianyou Shi

12 January 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JWJie Wang
Jie Wang
YCYuhang Chen
Yuhang Chen
XYXinwei Yang
Xinwei Yang
JHJianli Huang
Jianli Huang
YXYihua Xu
Yihua Xu
BWBo xian Wu
Bo xian Wu
Background: Chronic pruritus (CP) is a common and aggravating symptom associated with skin and systemic diseases. Although clinical reports suggest that Chinese herbal medicine (CHM) is safe and effective in Chronic pruritus treatment, evidence to prove it is lacking. Therefore, in this review, we evaluated the therapeutic effects and safety of Chinese herbal medicine for the treatment of Chronic pruritus.Methods: Nine databases were searched for relevant randomized controlled trials (RCTs) from the inception of the database to 20 April 2022. The randomized controlled trials that compared the treatment of Chinese herbal medicine or a combination of Chinese herbal medicine and conventional western medicine treatment (WM) with western medicine treatment intervention for patients with Chronic pruritus were selected. We evaluated the effects of treatment with Chinese herbal medicine on the degree of pruritus, the Dermatology Life Quality Index (DLQI) score, response rate, recurrence rate, and incidence of adverse events in patients with Chronic pruritus. The risk of bias in each trial was evaluated using the Cochrane Collaboration tool. The RevMan software (version 5.3) was used for performing meta-analyses to determine the comparative effects.Results: Twenty-four randomized controlled trials were included, compared with placebo, moderate-quality evidence from one study showed that Chinese herbal medicine was associated with reduced visual analogue scale (VAS) (MD: −2.08; 95% CI = −2.34 to −1.82). Compared with western medicine treatment, low-to moderate-quality evidence from 8 studies indicated that Chinese herbal medicine was associated with reduced visual analogue scale, 4 studies indicated that Chinese herbal medicine was associated with reduced Dermatology Life Quality Index (MD = −1.80, 95% CI = −2.98 to −.62), and 7 studies indicated that Chinese herbal medicine was associated with improved Effective rate (RR: 1.26; 95% CI = 1.19–1.34). Compared with combination of Chinese herbal medicine and western medicine treatment, 16 studies indicated that Chinese herbal medicine was associated with reduced visual analogue scale, 4 studies indicated that Chinese herbal medicine was associated with reduced Dermatology Life Quality Index (MD = −2.37, 95% CI = −2.61 to −2.13), and 13 studies indicated that Chinese herbal medicine was associated with improved Effective rate (RR: 1.28; 95% CI = 1.21–1.36). No significant difference in the occurrence of adverse events in using Chinese herbal medicine or western medicine treatment was reported.Conclusion: The efficacy of Chinese herbal medicine used with or without western medicine treatment was better than western medicine treatment in treating chronic pruritus. However, only a few good studies are available regarding Chronic pruritus, and thus, high-quality studies are necessary to validate the conclusions of this study.

24 November 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JHJian-Li Huang
Jian-Li Huang
YXYi-Hua Xu
Yi-Hua Xu
XYXinwei Yang
Xinwei Yang
JWJie Wang
Jie Wang
YZYu Zhu
Yu Zhu
BWBo xian Wu
Bo xian Wu

27 December 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
灿邹灿 邹
灿 邹
JXJia-Ling Xie
Jia-Ling Xie
QLQuan Luo
Quan Luo
YXYong-Hui Xiao
Yong-Hui Xiao
YLYu-Ru Li
Yu-Ru Li
HZHai-Yan Zhu
Hai-Yan Zhu

27 March 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CZCan Zou
Can Zou
YWYuxia Wang
Yuxia Wang
QCQiuyan Chen
Qiuyan Chen
JSJianyou Shi
Jianyou Shi
BWBo xian Wu
Bo xian Wu
QLQuan Luo
Quan Luo
Renal cell carcinoma (RCC) is a type of solid tumor with one of the highest incidences among urinary system malignancies, and its incidence continues to increase worldwide. The PI3K-AKT-mTOR signaling pathway, as a central signaling hub that regulates biological processes such as cell survival, proliferation, metabolism, and metastasis, often exhibits abnormal and sustained activation during the pathological progression of RCC. Dysregulation of this pathway synergistically promotes tumor progression through multiple mechanisms, including enhancing the survival and clonal expansion of tumor cells, inducing angiogenesis, driving metabolic reprogramming of the tumor microenvironment, and mediating treatment resistance. These pathological changes are closely associated with poor patient prognosis. Given the central role of the PI3K-AKT-mTOR signaling pathway in the pathogenesis of RCC, it has become a key target for targeted therapeutic intervention. Although multiple small-molecule inhibitors targeting this pathway have demonstrated potential for inhibiting tumor growth in preclinical studies and early-phase clinical trials, their clinical application still faces numerous challenges. Against this backdrop, combination therapy strategies offer a new approach to overcome the limitations of single-agent therapy, not only enhancing treatment efficacy but also potentially reducing the risk of drug resistance. Notably, natural products and their derivatives, due to their low toxicity, ability to modulate multiple targets, and specific inhibitory effects on cancer stem cells, are regarded as promising sensitizers in combination therapy. This article systematically reviews the pathological features of RCC and current clinical treatment strategies, with a focus on exploring the molecular regulatory mechanisms of the PI3K-AKT-mTOR signaling pathway in tumor progression, while highlighting the latest research advances in small-molecule inhibitors targeting this pathway. Integrating preclinical mechanistic studies and relevant clinical trial data, the limitations of existing agents are analyzed, and potential optimization directions are proposed, aiming to provide theoretical support and practical references for the clinical translation of precision therapy for RCC and to promote the transformation of pathway-based combination therapy models into clinical applications.